AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37326473
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of meropenem
Trial: 37326473
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of meropenem
Trial: 37326942
Drug: SHR2285 (25-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2285 (25-600 mg single ascending doses)
Trial: 37326942
Drug: SHR2285 (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2285 (100-400 mg multiple ascending doses)
Trial: 37327046
Drug: Self-reported number
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported number of doses
Trial: 37327046
Drug: Self-reported brand
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported brand of the first dose
Trial: 37327046
Drug: Self-reported brand
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported brand of the second dose
Trial: 37327046
Drug: Self-reported brand
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported brand of the third dose
Trial: 37327113
Drug: Romidepsin 10
RxNorm normalized name: romidepsin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romidepsin 10 mg/m2 IV on days 1, 8, and 15 plus lenalidomide 25 mg orally from days 1 to 21 of a 28-day cycle for up to 1 year
Trial: 37327230
Drug: Humanoid robot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanoid robot Pepper used at home by children with cochlear implants and their families for 1 month.
Trial: 37327369
Drug: Topical Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical Azithromycin
Trial: 37327369
Drug: Oral Doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Doxycycline
Trial: 37327461
Drug: Dato-DXd 6
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dato-DXd 6 mg/kg once every 3 weeks
Trial: 37327527
Drug: Apixaban (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (therapeutic doses)
Trial: 37327677
Drug: emtricitabine-tenofovir disoproxil
RxNorm normalized name: Emtricitabine-Tenofovir Disoproxil Fumarate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emtricitabine-tenofovir disoproxil fumarate (F/TDF) or emtricitabine-tenofovir alafenamide (F/TAF) given as a double dose once either 5 or 21 hours before ex vivo HIV-challenge.
Trial: 37328392
Drug: Biolimus A9™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biolimus A9™ drug coated balloon (BA9-DCB)
Trial: 37328736
Drug: Alirocumab (LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (LDL-C < 25 mg/dL)
Trial: 37328736
Drug: Placebo (LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (LDL-C < 25 mg/dL)
Trial: 37328736
Drug: Alirocumab (LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (LDL-C < 15 mg/dL)
Trial: 37328736
Drug: Placebo (LDL-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (LDL-C < 15 mg/dL)
Trial: 37328751
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted cognitive behaviour therapy (CaCBT)
Trial: 37328835
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose gemcitabine (Gem)
Trial: 37328835
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose gemcitabine and nab-paclitaxel (GemNab)
Trial: 37328855
Drug: Focused ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused ultrasound (FUS) at 220 kHz with systemically administered microbubbles, administered in three successive procedures at 2 week intervals.
Trial: 37328859
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg)
Trial: 37955825
Drug: Sotrovimab 500
RxNorm normalized name: sotrovimab 500 MG in 8 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrovimab 500 mg IV infusion
Trial: 37328890
Drug: Sotrovimab 2000
RxNorm normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Sotrovimab 2000 mg IV infusion
Trial: 37328890
Drug: Sotrovimab (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrovimab (dosing intervals to be defined)
Trial: 37328931
Drug: semaglutide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 0.1 mg
Trial: 37328931
Drug: semaglutide 0.2
RxNorm normalized name: SEMAGLUTIDE 0.25MG/0.375ML INJ PEN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 0.2 mg
Trial: 37328931
Drug: semaglutide 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 0.4 mg
Trial: 37328931
Drug: semaglutide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide (all doses pooled)
Trial: 37329361
Drug: Three preoperative
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three preoperative intravitreal (IVI) aflibercept injections with a monthly interval; the third injection was given intra-operatively (Group A)
Trial: 37329361
Drug: Single intra-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single intra-operative injection and two post-operative injections with a monthly interval (Group B)
Trial: 37329415
Drug: Bamlanivimab and
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bamlanivimab and etesevimab (BAM + ETE) - open-label weight-based dosing (WBD, n=94)
Trial: 37329633
Drug: Chios Mastiha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chios Mastiha Essential Oil (CMEO) 200 mg daily for 3 months
Trial: 37329891
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan 6.4 mg/kg intravenously every 3 weeks until disease progression, withdrawal, physician decision, or death
Trial: 37329900
Drug: KAN-101 (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAN-101 (0.15 mg/kg, 0.3 mg/kg, 0.6 mg/kg)
Trial: 37329900
Drug: KAN-101 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAN-101 (all doses)
Trial: 37329979
Drug: 2x taVNS
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x taVNS (twice daily)
Trial: 37329979
Drug: 1x taVNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x taVNS (once daily)
Trial: 37330484
Drug: Bioclear matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioclear matrix with injection molding technique
Trial: 37330928
Drug: Restrictive IV
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive IV fluid therapy
Trial: 37330974
Drug: Lumbar drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar drain (5 mL per hour) started within 72 hours after aneurysmal subarachnoid hemorrhage
Trial: 37330974
Drug: Lumbar drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar drain (5 mL per hour)
Trial: 37331369
Drug: Fruquintinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib (5 mg capsule) orally once daily on days 1-21 in 28-day cycles
Trial: 37331368
Drug: Etripamil 70
RxNorm normalized name: etripamil
DrugBank: Etripamil (DB12605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etripamil 70 mg nasal spray
Trial: 37331690
Drug: Intravenous diuretics
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diuretics (HFH event type)
Trial: 37331690
Drug: Randomized treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatment groups
Trial: 37331928
Drug: Transpalpebral external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transpalpebral external microcurrent electrical stimulation with the MacuMira device, 4 treatments in the first 2 weeks, and 2 further treatments at weeks 14 and 26.
Trial: 37331928
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control group (no active treatment).
Trial: 37332340
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy (SCRT) followed by chemotherapy and immunotherapy
Trial: 37332355
Drug: HFB30132A monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFB30132A monoclonal antibody
Trial: 37332638
Drug: Dopamine system-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine system-related biomarkers assessed by serial Iodine-123 Ioflupane dopamine transporter (DAT) imaging, genotyping, and levodopa equivalent daily dose (LEDD) recorded at each assessment.
Trial: 37332660
Drug: Low-dose ambrisentan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ambrisentan
Trial: 37332660
Drug: High-dose ambrisentan
RxNorm normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-dose ambrisentan
Trial: 37333093
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of age, sex, and three proteins (ANGPT2, CCL5, TIMP1)
Trial: 37333204
Drug: L-citrulline 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-citrulline 60 mg/kg every 6 hours for 72 hours
Trial: 37333529
Drug: Native Opportunities
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native Opportunities to Stop Hypertension (NOSH) intervention, which includes eight weekly tailored telenutrition counseling sessions with a registered dietitian on DASH eating goals and $30 weekly for purchasing DASH-aligned foods.
Trial: 37333529
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving printed educational materials about a low-sodium diet and eight weekly $30 grocery orders.
Trial: 37333833
Drug: High-definition home-based
RxNorm normalized name: ESIKA PRO HD COLOR HIGH DEFINITION COLOR SPF 20 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-definition home-based transcranial alternating current stimulation (HB-tACS) at 40 Hz for 20 minutes, targeting the left angular gyrus, administered over 14 weeks with at least five sessions per week.
Trial: 37334213
Drug: 6-month 45-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month 45-mg leuprolide acetate (LA) depot, administered intramuscularly at weeks 0 and 24
Trial: 37334213
Drug: 6-month 45-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month 45-mg leuprolide acetate (LA) depot
Trial: 37334295
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g of carbohydrates (CHO)
Trial: 37334295
Drug: 32 g
RxNorm normalized name: PEG-32 Glyceryl Laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 g of carbohydrates (CHO)
Trial: 37334295
Drug: Additional 16
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional 16 g of carbohydrates (CHO) if PG was still <3.0 mmol/L at 15 min and <4.0 mmol/L at 45 min post-initial treatment
Trial: 37334511
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus multiagent chemotherapy in Ph-negative ALL
Trial: 37334511
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus multiagent chemotherapy in Ph-positive ALL
Trial: 37334546
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonists (MRA) treatment for at least 6 months
Trial: 37334673
Drug: Chemotherapy (selected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (selected by treating physician)
Trial: 37335139
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICI) therapy
Trial: 37335552
Drug: D/C/F/TAF 675/150/200/10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D/C/F/TAF 675/150/200/10-mg FDC (test)
Trial: 37335552
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of separate agents: darunavir 600 mg, cobicistat 150 mg, emtricitabine/tenofovir alafenamide 200/10-mg FDC (reference)
Trial: 37335552
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of separate agents (reference)
Trial: 37335611
Drug: Voice-based digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice-based digital health solution to monitor long COVID symptoms using vocal biomarkers
Trial: 37335611
Drug: Co-development of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-development of a tailored voice-based digital health solution
Trial: 37335817
Drug: Mindfulness-Based Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Stress Reduction (MBSR) program, consisting of 8 weekly sessions lasting 2.5 hours each and a 6-hour silence retreat during week 6.
Trial: 37335963
Drug: mRNA-1273 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered concomitantly (Coad group)
Trial: 37335963
Drug: mRNA-1273 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 (50 µg) booster vaccination and first dose of recombinant zoster vaccine (RZV1) administered sequentially (Seq group)
Trial: 37335994
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Acupuncture and Doxylamine-Pyridoxine
Trial: 37336007
Drug: Online opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online opioid overdose and naloxone administration education (20-minute video)
Trial: 37336055
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel ≤12 mg/day
Trial: 37336533
Drug: Mavacamten (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavacamten (starting dose 2.5 mg/day, adjusted during the study)
Trial: 37336835
Drug: Preventative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventative therapy consultation
Trial: 37336835
Drug: Preventative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventative therapy prescription
Trial: 37336877
Drug: mRNA-1010 (50 µg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1010 (50 µg, 100 µg, or 200 µg)
Trial: 37336877
Drug: mRNA-1010 (25 µg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1010 (25 µg, 50 µg, or 100 µg)
Trial: 37337155
Drug: FOLFIRI-Ram (5-FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI-Ram (5-FU 2400 mg/m2)
Trial: 37337234
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein content (2.0 g of protein/kg/day)
Trial: 37337234
Drug: Standard protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protein content (1.3 g of protein/kg/day)
Trial: 37337261
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment As Usual (TAU)
Trial: 37337269
Drug: Periradicular administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periradicular administration of platelet-rich fibrin (PRF) during surgery
Trial: 37337295
Drug: Inhaled xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled xenon administered within 6 hours after the onset of symptoms of aSAH
Trial: 37337366
Drug: Cotadutide 600-μg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide 600-μg
Trial: 37337747
Drug: Glimepiride 1-2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 1-2 mg/day
Trial: 37338017
Drug: 0.1-20.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1-20.0 g/day alcohol use (moderate drinkers)
Trial: 37338017
Drug: >20.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >20.0 g/day alcohol use (heavy drinkers)
Trial: 37338017
Drug: 0.0 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 g/day alcohol use (non-drinkers)
Trial: 37338130
Drug: Telemedicine for
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemedicine for Reach, Education, Access, Treatment, and Ongoing Support (TREAT-ON) program
Trial: 37338150
Drug: Senaparib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senaparib (100 mg QD)
Trial: 37338154
Drug: MAS825 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS825 (10 mg/kg single i.v.) + standard of care (SoC)
Trial: 37338355
Drug: Radiomics features
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiomics features in standard-dose CT (model I)
Trial: 37338355
Drug: Demographics in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demographics in standard-dose CT
Trial: 37338393
Drug: Bemnifosbuvir, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemnifosbuvir, an oral antiviral drug targeting viral RNA polymerase, dosage and duration not specified.
Trial: 37338445
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure treatment focusing on sexual assault trauma
Trial: 37338445
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure treatment not focusing on sexual assault trauma
Trial: 37338608
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K supplementation with oral bisphosphonate, calcium and/or vitamin D
Trial: 37338615
Drug: Clonidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (75 μg twice a day)
Trial: 37338893
Drug: ApTOLL 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApTOLL 0.2 mg/kg
Trial: 37338893
Drug: ApTOLL 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApTOLL 0.05 mg/kg
Trial: 37338898
Drug: Technology Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology Assisted Stepped Collaborative Care (TĀCcare) - 12 weekly sessions of cognitive behavioral therapy via telehealth and/or pharmacotherapy.
Trial: 37338906
Drug: Adapted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted therapy (ADT) with nicotine patch (NP) and pharmacotherapy adaptations (varenicline and bupropion+NP)
Trial: 37338906
Drug: Adapted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted therapy (ADT) with pharmacotherapy adaptations
Trial: 37338929
Drug: Remote monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote monitoring solutions and digital alerting tools
Trial: 37338929
Drug: Recommendations for
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendations for enhancing integration of remote sensing solutions
Trial: 37339186
Drug: Ipatasertib 400
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib 400 mg daily plus rucaparib 400 mg twice daily
Trial: 37339254
Drug: Trifluridine/tipiracil 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil 25 mg/m2 (days 1-5 of 14-day cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle)
Trial: 37339342
Drug: Self-tell notification
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-tell notification (treatment as usual)
Trial: 37625088
Drug: DARE-HRT1 IVR1
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DARE-HRT1 IVR1 (E2 80 μg/d with P4 4 mg/d)
Trial: 37625088
Drug: DARE-HRT1 IVR2
RxNorm normalized name: Darexaban
DrugBank: Darexaban (DB12289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DARE-HRT1 IVR2 (E2 160 μg/d with P4 8 mg/d)
Trial: 37339441
Drug: d-Amphetamine Transdermal
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine Transdermal System